# Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

> **NCT01048619** · PHASE1 · COMPLETED · sponsor: **Traws Pharma, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** ON 01910.Na

## Key facts

- **NCT ID:** NCT01048619
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2014-11
- **Final completion:** 2015-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01048619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01048619, "Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01048619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*